Already a member? Sign in
Lisinopril is an ACE-inhibitor used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Elevated blood pressure | 458 | 88 |
|
|
|
|
|
| Hypertension | 307 | 32 |
|
|
|
|
|
| Other | 99 | 8 |
|
|
|
||
| General health | 38 | 9 |
|
|
|
|
|
| Chronic Kidney Disease | 19 | 2 |
|
|
|||
| CHF (Congestive heart failure) | 17 | 1 |
|
See all 910 patients currently taking Lisinopril
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Lisinopril
| Dry cough | 10 | |
|---|---|---|
| Cough | 7 | |
| Dizziness with hypotension upon standing | 6 | |
| Persistent cough | 4 | |
| Sex drive (libido) decreased | 4 | |
| Low blood pressure | 4 | |
| See all 33 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Lisinopril. See all 24 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Doctor's advice | 76 | ||
| Side effects too severe | 52 | ||
| Other | 28 | ||
| Did not seem to work | 16 | ||
| Course of treatment ended | 11 | ||
| Personal research | 6 | ||
| Expense | 3 | ||
| Change in health plan coverage | 3 | ||
| Not indicated | 2 |
Adherence
Taking treatment as prescribed
Adherence of Lisinopril
Always |
136 | 88% |
|
|---|---|---|---|
Usually |
12 | 8% |
|
Sometimes |
1 | 1% |
|
Never |
5 | 3% |
|
Burden
Difficulty being on treatment
Burden of Lisinopril
Very |
2 | 1% |
|
|---|---|---|---|
Somewhat |
4 | 3% |
|
A little |
13 | 8% |
|
Not at all |
135 | 88% |
|
Cost
Paid out of pocket
Cost of Lisinopril
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
3 | 3% |
|
< $25 |
109 | 97% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 26, 2012.